9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
The DOI matches its Crossref record; 77 of the 81 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although SGLT2 inhibitor use was not incorporated into American Diabetes Association guidelines until 2019,48”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [48]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (40).”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Research works printed but not linked: 6
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lexicon Pharmaceuticals . FDA to review ZynquistaTM (sotagliflozin) as potential treatment for type 1 diabetes [Internet], 2018. Available from http://www.lexpharma.com/media-center/news/673-fda-to-review-zynquista-sotagliflozin-as-potential-treatment-for-type-1-diabetes. Accessed 30 September 2018
- Institute for Clinical and Economic Review . Controversies in the management of patients with type 2 diabetes [Internet], December 2014. Available from https://icer-review.org/wp-content/uploads/2015/03/CEPAC-T2D-Final-Report-December-22.pdf. Accessed 9 November 2018
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
- Lipska, 2017, Human insulin for type 2 diabetes: an effective, less-expensive option, 23
Cited by
Items 301–400 of 773
Lin, S., Chang, S., Kuo, C., Lin, W., Chiou, M., & Huang, Y. (2020) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-020-03207-0 · Cited by 18
Arefin, A., & Gage, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054785 · Cited by 17
Yan, L., Li, L., Peng, Y. D., Song, G., Ye, S., Du, L. Y., Hou, J. N., & Ji, Q. H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0646-y · Cited by 17
Yoo, J. H., Cho, Y. K., Lee, J., Kim, H. S., Kang, Y. M., Jung, C. H., Park, J., & Lee, W. J. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0658-7 · Cited by 18
Gallo, S., Calle, R. A., Terra, S. G., Pong, A., Tarasenko, L. C., & Raji, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00867-1 · Cited by 17
Carrasco-Sánchez, F. J., Rodríguez, J. M. F., Ena, J., Gómez‐Huelgas, R., & Carretero‐Gómez, J. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2020.06.009 · Cited by 17
Wang, T., Zhang, F., Wang, X., Li, X., Ling, H., Lv, D., Yin, X., & Lü, Q. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13134 · Cited by 39
Evaluation of General Health Status in Diabetic Patients Using Short Form Health Survey (SF-36)
Ibrahimy, A. S. A., & Rabeea, I. S. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200814133535 · Cited by 16
Personalized Management of Type 2 Diabetes
Peter, P. R., & Lupsa, B. C. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1244-0 · Cited by 17
Incretin‐based drugs and risk of lung cancer among individuals with type 2 diabetes
Rouette, J., Yin, H., Yu, O. H. Y., Bouganim, N., Platt, R. W., & Azoulay, L. (2020) · Diabetic Medicine · doi:10.1111/dme.14287 · Cited by 16
Capehorn, M., Ghani, Y., Hindsberger, C., Johansen, P., & Jódar, E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00796-z · Cited by 19
Jimeno, C., Sy, R. A., Pena, P. D., Cipriano, C. C., Tan, R., Panelo, A., & Ng, J. Y. S. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049737 · Cited by 16
Konieczyński, P., Gappa, M., Wesołowski, M., Pinto, E., & Almeida, A. A. (2022) · Foods · doi:10.3390/foods11050667 · Cited by 16
Belthangady, C., Giampanis, S., Jankovic, I., Stedden, W., Alves, P., Chong, S., Knott, C., & Norgeot, B. (2022) · Nature Communications · doi:10.1038/s41467-022-33732-9 · Cited by 17
RSSDI consensus recommendations on insulin therapy in the management of diabetes
(extended), E. P., Chawla, R., Makkar, B. M., Aggarwal, S., Bajaj, S., Das, A. K., Ghosh, S. K., Gupta, A., Gupta, S., Jaggi, S., et al. (2019) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-019-00783-6 · Cited by 16
Zoungas, S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13968 · Cited by 17
Cardiovascular risk management in type 1 diabetes
Teoh, I. H., Elisaus, P., & Schofield, J. D. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01400-9 · Cited by 15
Liu, D., Han, X., Zou, W., Yang, Z., Peng, J., Li, Y., Liu, Y., Jia, M., Liu, W., Li, H., et al. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01748-9 · Cited by 16
“…revealed that long-term consumption of a high-fat diet disrupted the body’s glucose and lipid metabolism, resulting in impaired reproductive function, such as testicular tissue damage, germ cell apoptosis and a decrease in sperm quality, which was consistent with previous studies [30, 31].”
Vaccaro, O., Lucisano, G., Masulli, M., Bonora, E., Prato, S. D., Rivellese, A. A., Giorda, C. B., Mocarelli, P., Squatrito, S., Maggioni, A. P., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00361 · Cited by 15
Treatment strategies for hypertension in patients with type 1 diabetes
Katsimardou, A., Imprialos, K. P., Stavropoulos, K., Sachinidis, A. G., Doumas, M. N., & Athyros, V. G. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1729124 · Cited by 17
Glastras, S. J., Cohen, N. D., Dover, T., Kilov, G., MacIsaac, R. J., McGill, M. J., & Fulcher, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041091 · Cited by 17
Type 2 diabetes in older patients: an analysis of the DPV and DIVE databases
van Mark, G., Tittel, S. R., Sziegoleit, S., Putz, F. J., Durmaz, M., Bortscheller, M., Buschmann, I. R., Seufert, J., Holl, R. W., & Bramlage, P. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820958296 · Cited by 16
Qu, L., Liang, X., Tian, G., Zhang, G.-L., Wu, Q., Huang, X., Cui, Y., Liu, Y., Shen, Z., Ma, G., et al. (2022) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-021-2885-9 · Cited by 15
Potential Therapeutic Targets and Promising Agents for Combating NAFLD
Umemura, A., Kataoka, S., Okuda, K., Seko, Y., Yamaguchi, K., Moriguchi, M., Okanoue, T., & Itoh, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10040901 · Cited by 15
Jung, H. N., Cho, Y. K., Min, S. H., Kim, H. S., Kim, Y., Park, J., Lee, W. J., & Jung, C. H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.870722 · Cited by 17
Puangpet, T., Pongkunakorn, T., Chulkarat, N., Bunlangjit, C., Surawit, A., Pinsawas, B., Mongkolsucharitkul, P., & Mayurasakorn, K. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01823-7 · Cited by 18
Schäfer, Z., Mathisen, A., Thomsen, T. R., Rossing, P. R., & Kirketerp‐Møller, K. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110799 · Cited by 15
Xing, Y., Xie, X., Xu, J., Liu, J., He, Q., Yang, W., Zhang, N., Li, X., Wang, L., Fu, J., et al. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1649251 · Cited by 15
Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?
Eckel, R. H., Farooki, A., Henry, R. R., Koch, G. G., & Leiter, L. A. (2019) · Clinical Diabetes · doi:10.2337/cd19-0001 · Cited by 17
Hsieh, Y., Liao, Y., Li, C., Lin, J., Weng, C., Lin, C., Lo, C., Huang, K., Huang, J., Lin, C., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3226 · Cited by 16
Ferreira‐Hermosillo, A., Molina-Ayala, M., Molina-Guerrero, D., Garrido-Mendoza, A. P., Ramírez‐Rentería, C., Mendoza‐Zubieta, V., Espinosa-Cárdenas, E., & Mercado, M. (2020) · Trials · doi:10.1186/s13063-020-4121-x · Cited by 15
Metformin: still the sweet spot for CV protection in diabetes?
Rena, G., Mordi, I. R., & Lang, C. C. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.10.018 · Cited by 16
Lee, M., Lee, C., Chang, L., Chang, C., Zhang, J., Lee, M., Wang, J., & Chen, S. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1452 · Cited by 16
Ye, P., Feng, L., Zhang, D., Li, R., Wen, Y., Tong, X., Shi, S., & Dong, C. (2023) · Stem Cells International · doi:10.1155/2023/1429642 · Cited by 15
“Metformin is an oral hypoglycemic drug and has been applied in first-line treatment for type 2 diabetes worldwide [9].”
BackgroundStan, S. I., Biciuşcă, V., Clenciu, D., Mitrea, A., Boldeanu, M. V., Durand, P., & Dănoiu, S. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2629 · Cited by 18
“Instead, effects on the improvement of inflammation, ballooning and fibrosis have been reported in a small number of patients, requiring additional studies on histology [122].”
BackgroundPatel, K. S., & Carbone, A. M. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019859323 · Cited by 15
Dhopeshwarkar, N., Brensinger, C. M., Bilker, W. B., Soprano, S. E., Flory, J., Dawwas, G. K., Gagne, J. J., Hennessy, S., & Leonard, C. E. (2020) · Scientific Reports · doi:10.1038/s41598-020-66668-5 · Cited by 14
Patel, D. K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13224 · Cited by 14
Wong, C. K. H., Tang, E. H. M., Man, K. K. C., Chan, E. W., Wong, I. C. K., & Lam, C. L. K. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.005 · Cited by 14
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
Ahmad, M. I., & Shapiro, M. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00913-8 · Cited by 14
Martins, R. B., Ordaz-Briseño, S. A., Flores-Hernández, S., Bós, Â. J. G., Baptista-Rosas, R. C., & Mercado-Sesma, A. R. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00711-y · Cited by 15
Treatment burden and perceptions of glucose-lowering therapy among people living with diabetes
González-Saldívar, G., Millán-Alanís, J. M., González‐González, J. G., Sánchez-Gómez, R. A., Obeso-Fernández, J., McCoy, R. G., Maraka, S., Brito, J. P., Ospina, N. S., Oyervides-Fuentes, S., et al. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.04.002 · Cited by 15
Hung, C., Chang, Y., & Wang, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214101 · Cited by 14
Overcoming barriers to the use of metformin: patient and provider perspectives
Flory, J., Keating, S. J., Guelce, D., & Mushlin, A. I. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s211614 · Cited by 14
Lv, Q., Shen, J., Miao, L., Ye, B., Schepers, C., Plat, A. W., & Shi, Y. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00819-9 · Cited by 16
Kim, S. G., Kim, K. J., Yoon, K., Chun, S. W., Park, K. S., Choi, K. M., Lim, S. K., Mok, J., Lee, H. W., Seo, J. A., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14085 · Cited by 14
Qiao, H., Li, Y., Xu, B., Lu, Z., Zhang, J., Meng, D., He, S., & Huang, J. (2022) · Cardiology · doi:10.1159/000527384 · Cited by 13
Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
Kim, J. H., Lee, J., Han, K., Kim, J., & Kwon, H. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0275 · Cited by 13
“The guidelines were initially published in 2019 [30,31].”
Cho, Y. K., Lee, J., Kim, H. S., Park, J., Jung, C. H., & Lee, W. J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00881-3 · Cited by 13
Diabetes and CVD Risk: Special Considerations in African Americans Related to Care
Wittwer, J. A., Golden, S. H., & Joseph, J. J. (2020) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-020-00648-2 · Cited by 14
Cieslik, L., Cresswell, N. R., Fineberg, D., Mariani, J. A., & Patel, H. C. (2020) · Internal Medicine Journal · doi:10.1111/imj.15137 · Cited by 14
Geller, A. I., Conrad, A. O., Weidle, N. J., Mehta, H., Budnitz, D. S., & Shehab, N. (2021) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5212 · Cited by 13
Hirose, N., Tsujimoto, N., Katayose, T., & Chin, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14600 · Cited by 14
Memon, R. A., Akbariromani, H., Vohra, R. R., Kundi, H., Saleem, F., Ghaffari, M. A. Z., Haas, D. C., & Khan, A. (2022) · Cureus · doi:10.7759/cureus.27277 · Cited by 13
Kim, J., Bae, Y., & Kang, H. (2022) · Korean Journal of Family Medicine · doi:10.4082/kjfm.22.0005 · Cited by 13
Comparison of efficacy of anti-diabetics on non-diabetic NAFLD: A network meta-analysis
Jin, D., Cui, Z., Jin, S., Zhou, T., Guo, B., Gao, P., & Li, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1096064 · Cited by 13
Semantically enabling clinical decision support recommendations
Seneviratne, O. W., Das, A. K., Chari, S., Agu, N. N., Rashid, S. M., McCusker, J. P., Franklin, J. S., Qi, M., Bennett, K. P., Chen, C.-H., et al. (2023) · Journal of Biomedical Semantics · doi:10.1186/s13326-023-00285-9 · Cited by 16
“As a proof-of-concept, we modeled 41 cited research publications in the pharmacologic recommendations and cardiovascular complications chapters in the ADA CPG. 19 of these publications came from the 2018 ADA CPG [94], and 22 came from the 2019 ADA CPG [103].”
MethodWang, T., Yang, J. Y., Buse, J. B., Pate, V., Tang, H., Barnes, E. L., Sandler, R. S., & Stürmer, T. (2019) · Diabetes Care · doi:10.2337/dc19-0162 · Cited by 13
Lee, J., Cho, Y. K., Kim, H. S., Jung, C. H., Park, J., & Lee, W. J. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s231272 · Cited by 14
Hur, K. Y., Kim, M. K., Ko, S., Han, M., Lee, D. W., Kwon, H., & Korean Society of Nephrology (2020) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.20.012 · Cited by 14
Lee, I. (2020) · Diabetes and Vascular Disease Research · doi:10.1177/1479164120909030 · Cited by 15
Evans, M., Moes, R. G. J., Pedersen, K. S., Gundgaard, J., & Pieber, T. R. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01332-y · Cited by 14
Ito, H., Antoku, S., Izutsu, T., Kusano, E., Matsumoto, S., Yamasaki, T., Mori, T., & Togane, M. (2020) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01935-3 · Cited by 16
Bachmann, K. N., Roumie, C. L., Wiese, A. D., Grijalva, C. G., Buse, J. B., Bradford, R. L., Zalimeni, E., Knoepp, P., Dard, S., Morris, H., et al. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.637 · Cited by 13
Yabe, D., Higashiyama, H., Kadowaki, T., Origasa, H., Shimomura, I., Watada, H., Tobe, K., Iglay, K., Tokita, S., & Seino, Y. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001361 · Cited by 13
Saleh, S. A., Hanna, G. S., El‐Nabi, S. H., El-Domiaty, H. F., Shabaan, A., & Ewida, S. F. (2020) · Journal of Genetics · doi:10.1007/s12041-020-01196-9 · Cited by 14
Dirr, E. W., Urdaneta, M. E., Patel, Y., Johnson, R. D., Campbell‐Thompson, M., & Otto, K. J. (2020) · Bioelectronics in Medicine · doi:10.2217/bem-2020-0006 · Cited by 14
High concurrent use of sulfonylureas and antimicrobials with drug interactions causing hypoglycemia
Pilla, S. J., Pitts, S. I., & Maruthur, N. M. (2022) · Journal of Patient Safety · doi:10.1097/pts.0000000000000739 · Cited by 12
Chen, P.-C., Hong, C.-T., Chen, W.-T., Chan, L., & Chien, L.-N. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.01.007 · Cited by 12
Managing drug therapy-related problems and assessment of chronic diabetic wounds
Mahendran, M. I. M. S., Gopalakrishnan, V., Saravanan, V., Ramasamy, D., Jothimani, P., Balasubramanian, M., Singh, A. K., & Vaithianathan, R. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2414893 · Cited by 13
Nappi, F., Verde, A. L., Carfora, G., Garofalo, C., Provenzano, M., Sasso, F. C., & Nicola, L. D. (2019) · Medicina · doi:10.3390/medicina55080462 · Cited by 13
Ji, L., Du, Y., Xu, M., Zhou, X., Mo, Z., Ma, J., Li, J., Li, Y., Lin, J., Wang, Y., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05392-9 · Cited by 12
Mohan, V., Mukherjee, J. J., Das, A. K., Seshadri, K., & Dasgupta, A. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100103 · Cited by 13
Hunt, L. M., Arndt, E., Bell, H. S., & Howard, H. (2021) · Journal of Bioethical Inquiry · doi:10.1007/s11673-021-10119-x · Cited by 13
Suzuki, R., Kazumori, K., Usui, T., & Shinohara, M. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13923 · Cited by 12
Gao, Y., Peterson, E. D., & Pagidipati, N. J. (2019) · Clinical Cardiology · doi:10.1002/clc.23252 · Cited by 12
Evaluation of vitamin B12 monitoring in patients on metformin in urban ambulatory care settings
Longo, S. L., Ryan, J. M., Sheehan, K., Reid, D. J., Conley, M. P., & Bouwmeester, C. J. (2019) · Pharmacy Practice · doi:10.18549/pharmpract.2019.3.1499 · Cited by 12
Bornyl Derivatives of p-(Benzyloxy)Phenylpropionic Acid: In Vivo Evaluation of Antidiabetic Activity
Kuranov, S. O., Luzina, O. A., Khvostov, M. V., Baev, D. S., Kuznetsova, D., Zhukova, N., Vassiliev, P. M., Кочетков, А. Н., Tolstikova, T. G., & Salakhutdinov, N. F. (2020) · Pharmaceuticals · doi:10.3390/ph13110404 · Cited by 13
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Lamos, E. M., Kristan, M. M., Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1917374 · Cited by 12
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
(2019) · JAMA · doi:10.1001/jama.2019.2702 · Cited by 12
Tran, M. N., & Lee, S. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/3082109 · Cited by 16
Kim, H. J., Kim, Y. S., Lee, C. B., Choi, M. G., Chang, H., Kim, S. K., Yu, J. M., Kim, T. H., Lee, J. H., Ahn, K. J., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0628-0 · Cited by 12
Handelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01126-x · Cited by 12
Pradhan, R., Yin, H., Yu, O. H. Y., & Azoulay, L. (2019) · Drug Safety · doi:10.1007/s40264-019-00892-5 · Cited by 12
Tuccinardi, D., Giorgino, R., Pieralice, S., Watanabe, M., Maggi, D., Palermo, A., Defeudis, G., Fioriti, E., Pozzilli, P., & Manfrini, S. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01634-1 · Cited by 12
Tahmi, M., Benitez, R., & Luchsinger, J. A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240495 · Cited by 13
Annisa, B. S., Puspitasari, C. E., & Aini, S. R. (2021) · Sasambo Journal of Pharmacy · doi:10.29303/sjp.v2i1.74 · Cited by 18
Jin, H. Y., Lee, K. A., Kim, Y. J., Gwak, I. S., Park, T. S., Yeom, S. W., & Kim, J. S. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.06.006 · Cited by 12
Profiling of patients with type 2 diabetes based on medication adherence data
Markovič, R., Grubelnik, V., Završnik, T., Vošner, H. B., Kokol, P., Perc, M., Marhl, M., Završnik, M., & Završnik, J. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1209809 · Cited by 13
Hong, J. H., Moon, J. S., Seong, K., & Lim, S. K. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110872 · Cited by 11
Metformin Indications, Dosage, Adverse Reactions, and Contraindications
Stoica, R. A., Ștefan, D. S., Rizzo, M., Suceveanu, A., Suceveanu, A. P., Serafinceanu, C., & Stoian, A. P. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.88675 · Cited by 17
Sesti, G., Bardtrum, L., Dağdelen, S., Halladin, N., Haluzík, M., Örsy, P., Rodríguez, M., & Aroda, V. R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13957 · Cited by 11
Wong, C. K. H., Man, K. K. C., Shi, M., Chan, E. W., Ho, C. W., Tse, E. T. Y., Wong, I. C. K., & Lam, C. L. K. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002999 · Cited by 11
Mazurina, N. V., Артамонова, Е. В., Beloyartseva, M., Volkova, E., Петровна, Г. И., Troshina, E. A., Tjulandin, S. A., & Chubenko, V. A. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2020.4.200566 · Cited by 11
Hussain, M., Elahi, A., Iqbal, J., Ghafoor, M. B., Rehman, H., & Akhtar, S. (2021) · Cureus · doi:10.7759/cureus.14268 · Cited by 11
Schroeder, E. B., Neugebauer, R. S., Reynolds, K., Schmittdiel, J. A., Loes, L., Dyer, W., Pimentel, N., DESAI, J. R., Vazquez‐Benitez, G., Ho, P. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.26605 · Cited by 11
Exercise Testing in Individuals With Diabetes, Practical Considerations for Exercise Physiologists
Kosinski, C., Besson, C., & Amati, F. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01257 · Cited by 13
C-peptide concentrations in patients with type 2 diabetes treated with insulin
Uzunlulu, M., Oğuz, A., Bahadır, M. A., Erbakan, A. N., Keskinler, M. V., & Mesçi, B. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.11.010 · Cited by 11
Cheng, C., Wang, C., Lin, H.-W., Chang, T.-Y., Lin, H.-J., Chou, C., & Lin, F. (2020) · Scientific Reports · doi:10.1038/s41598-020-62646-z · Cited by 12
Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
Goldman, J. D. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13226 · Cited by 11
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S90-S102
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4212810717
- Cited by
- 739
- References
- 81
- Citations by year
- 2026: 12 · 2025: 28 · 2024: 30 · 2023: 47 · 2022: 69 · 2021: 126 · 2020: 246 · 2019: 181
- FWCI
- 21.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Societies, Medical, United States, Practice Guidelines as Topic, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.